| 0.2393 0.029 (13.63%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.35 | 1-year : | 0.43 |
| Resists | First : | 0.3 | Second : | 0.37 |
| Pivot price | 0.27  |
|||
| Supports | First : | 0.2 | Second : | 0.16 |
| MAs | MA(5) : | 0.22 |
MA(20) : | 0.29 |
| MA(100) : | 0.71 |
MA(250) : | 0.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10 |
D(3) : | 7.6 |
| RSI | RSI(14): 29.8 |
|||
| 52-week | High : | 2.56 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TCRX ] has closed above bottom band by 28.4%. Bollinger Bands are 37.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.24 - 0.24 | 0.24 - 0.25 |
| Low: | 0.21 - 0.21 | 0.21 - 0.21 |
| Close: | 0.24 - 0.24 | 0.24 - 0.24 |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Thu, 01 Oct 2026
A CEO receives stock with 75% conditionally vesting on a trial milestone or in 2030 at TScan Therapeutics (TCRX). - Stock Titan
Fri, 25 Sep 2026
Three parties report shared voting power over more than 5% of TScan Therapeutics (TCRX). - Stock Titan
Wed, 02 Sep 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors - GlobeNewswire
Wed, 12 Aug 2026
TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results - Quiver Quantitative
Wed, 12 Aug 2026
TScan Therapeutics Reports $30.4 Million Q2 Net Loss | TCRX Stock News - Quiver Quantitative
Wed, 12 Aug 2026
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 5.436e+007 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 1,750 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.1566e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 901.3 % |
| Return on Equity (ttm) | -31.6 % |
| Qtrly Rev. Growth | 7.11e+006 % |
| Gross Profit (p.s.) | -57.72 |
| Sales Per Share | -84.05 |
| EBITDA (p.s.) | -7.74737e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.26 |
| Dividend | 0 |
| Forward Dividend | 2.49e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|